Kaposi's sarcoma as a model for cancer immunotherapy

Trends in Molecular Medicine

Volumn 10, Issue 4, 2004, Pages 187-193

  Stebbing, Justin ^a   Bower, Mark ^a   Srivastava, Pramod ^b  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; ALPHA 2 MACROGLOBULIN; ALPHA INTERFERON; AMYLOID BETA PROTEIN; ANTIBODY; ANTIGEN; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN E4; CANCER VACCINE; CD20 B9E9 FUSION PROTEIN ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; FREUND ADJUVANT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HLA ANTIGEN CLASS 1; INTERLEUKIN 4; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEINASE; RNA DIRECTED DNA POLYMERASE; TRANSACTIVATOR PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANTIGEN DETECTION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CARCINOGENESIS; CELL STIMULATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; GENE SEQUENCE; GRANULOMA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE FUNCTION TEST; IMMUNE SYSTEM; IMMUNIZATION; KAPOSI SARCOMA; KIDNEY CARCINOMA; LIFE CYCLE; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; T LYMPHOCYTE; THEORETICAL MODEL; TUMOR CELL; VIRUS REPLICATION;

ANIMALS; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HEAT-SHOCK PROTEINS; HUMANS; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MODELS, BIOLOGICAL; NEOPLASMS; SARCOMA, KAPOSI;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 1642587776     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2004.02.006     Document Type: Review

References (79)

1. Siegel J.H., et al. Disseminated visceral Kaposi's sarcoma. Appearance after human renal homograft operation. J. Am. Med. Assoc. 207:1969;1493-1496.
2. Myers B.D., et al. Kaposi sarcoma in kidney transplant recipients. Arch. Intern. Med. 133:1974;307-311.
3. Penn I. Kaposi's sarcoma in organ transplant recipients: report of 20 cases. Transplantation. 27:1979;8-11.
4. Euvrard S., et al. Skin cancers after organ transplantation. N. Engl. J. Med. 348:2003;1681-1691.
5. Klein G., et al. Demonstration of resistance against methylcholanthrene- induced sarcomas in the primary autochthonous host. Cancer Res. 20:1960;1561-1562.
6. Klein G. Tumor antigens. Annu. Rev. Microbiol. 20:1966;223-252.
7. Burnet F.M. Immunological aspects of malignant disease. Lancet. 1:1967;1171-1174.
8. Burnet F.M. Immunological surveillance in neoplasia. Transplant. Rev. 7:1971;3-25.
9. Bayer R., Oppenheimer G.M. AIDS Doctors, Voices from the Epidemic, an Oral History. 2002;Oxford University Press.
10. Stebbing J., et al. Insights into the molecular biology and sero-epidemiology of Kaposi's sarcoma. Curr. Opin. Infect. Dis. 16:2003;25-31.
11. Barre-Sinoussi F., et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 220:1983;868-871.
12. Pearl L.H., Taylor W.R. A structural model for the retroviral proteases. Nature. 329:1987;351-354.
13. Miller M., et al. Crystal structure of a retroviral protease proves relationship to aspartic protease family. Nature. 337:1989;576-579.
14. Arnold E., et al. Structure of HIV-1 reverse transcriptase/DNA complex at 7 A resolution showing active site locations. Nature. 357:1992;85-89.
15. Kohlstaedt L.A., et al. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science. 256:1992;1783-1790.
16. Stebbing J., et al. New insights into the immunology and evolution of HIV. Cell Res. 13:2003;1-7.
17. Palella F.J. Jr, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection HIV outpatient study investigators. N. Engl. J. Med. 338:1998;853-860.
18. Hammer S.M. Increasing choices for HIV therapy. N. Engl. J. Med. 346:2002;2022-2023.
19. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J. Natl. Cancer Inst. 92:2000;1823-1830.
20. Stebbing J., et al. Kaposi's sarcoma - an update. Int. J. STD AIDS. 14:2003;225-227.
21. Portsmouth S., et al. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS. 17:2003;F17-F22.
22. Peyromaure M., et al. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients. J. Urol. 169:2003;2110-2112.
23. Jacobson L.P., et al. Impact of potent anti-retroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1 infected individuals. Multicenter AIDS Cohort Study. J. Acquir Immune Defic. Syndr. 21:(Suppl 1):1999;s34-s41.
24. Bower M., et al. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS. 13:1999;2105-2111.
25. Sgadari C., et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat. Med. 8:2002;225-232.
26. Ensoli B., et al. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature. 345:1990;84-86.
27. Stebbing J., et al. Kaposi's sarcoma-associated herpesvirus cytotoxic T lymphocytes recognize and target Darwinian positively selected autologous K1 epitopes. J. Virol. 77:2003;4306-4314.
28. Wilkinson J., et al. Identification of Kaposi's sarcoma-associated herpesvirus (KSHV or HHV-8)-specific cytotoxic T lymphocyte (CTL) epitopes and evaluation of reconstitution of KSHV-specific responses in HIV-1 infected patients receiving HAART. J. Virol. 76:2002;2634-2640.
29. Sirianni M.C., et al. NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi's sarcoma. Eur. J. Immunol. 32:2002;2711-2720.
30. Stebbing J., et al. Paclitaxel for anthracycline-resistant AIDS-related Kaposi's sarcoma: clinical and angiogenic correlations. Ann. Oncol. 14:2003;1660-1666.
31. Langford A., et al. Regression of oral Kaposi's sarcoma in a case of AIDS on zidovudine (AZT). Br. J. Dermatol. 120:1989;709-713.
32. Murdaca G., et al. Complete remission of AIDS/Kaposi's sarcoma after treatment with a combination of two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor. AIDS. 16:2002;304-305.
33. Stebbing J., et al. The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br. J. Cancer. 85:2001;953-958.
34. Stebbing J., Gore M. Preventing relapse in melanoma. Curr. Oncol. Rep. 2:2000;205-208.
35. Brown C.K., Kirkwood J.M. Medical management of melanoma. Surg. Clin. North Am. 83:2003;283-322.
36. Whelan M., et al. Cancer immunotherapy: an embarrassment of riches? Drug Discov. Today. 8:2003;253-258.
37. Stebbing J., et al. Disease associated dendritic cells respond to disease-specific antigens through the common heat shock protein receptor. Blood. 102:2003;1806-1814.
38. Harding C.V. Class I MHC presentation of exogenous antigens. J. Clin. Immunol. 16:1996;90-96.
39. Nijman H.W., et al. Antigen capture and major histocompatibility class II compartments of freshly isolated and cultured human blood dendritic cells. J. Exp. Med. 182:1995;163-174.
40. Mayordomo J.I., et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1:1995;1297-1302.
41. Zitvogel L., et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183:1996;87-97.
42. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu. Rev. Immunol. 20:2002;395-425.
43. Chun T.W., et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 94:1997;13193-13197.
44. Chun T.W., et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 387:1997;183-188.
45. Finzi D., et al. Latent infection of CD4+T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5:1999;512-517.
46. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 392:1998;245-252.
47. Binder R.J., et al. CD91: a receptor for heat shock protein gp96. Nat. Immunol. 1:2000;151-155.
48. Singh-Jasuja H., et al. The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor. Eur. J. Immunol. 30:2000;2211-2215.
49. Zheng H., et al. Cell surface targeting of heat shock protein gp96 induces dendritic cell maturation and antitumor immunity. J. Immunol. 167:2001;6731-6735.
50. Srivastava P.K., Amato R.J. Heat shock proteins: the 'swiss army knife' vaccines against cancers and infectious agents. Vaccine. 19:2001;2590-2597.
51. Tamura Y., et al. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science. 278:1997;117-120.
52. Blachere N.E., et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J. Exp. Med. 186:1997;1315-1322.
53. Panaretou B., et al. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J. 17:1998;4829-4836.
54. Roe S.M., et al. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 42:1999;260-266.
55. Vogen S., et al. Radicicol-sensitive peptide binding to the N-terminal portion of GRP94. J. Biol. Chem. 277:2002;40742-40750.
56. Queitsch C., et al. Hsp90 as a capacitor of phenotypic variation. Nature. 417:2002;618-624.
57. Mitchell-Olds T., Knight C.A. Evolution. Chaperones as buffering agents? Science. 296:2002;2348-2349.
58. Udono H., et al. Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo. Proc. Natl. Acad. Sci. U. S. A. 91:1994;3077-3081.
59. Nieland T.J., et al. Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94. Proc. Natl. Acad. Sci. U. S. A. 93:1996;6135-6139.
60. Belli F., et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J. Clin. Oncol. 20:2002;4169-4180.
61. Basu S., et al. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity. 14:2001;303-313.
62. Langenkamp A., et al. Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat. Immunol. 1:2000;311-316.
63. Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179:1994;1109-1118.
64. Lipsker D., et al. Heat shock proteins 70 and 60 share common receptors which are expressed on human monocyte-derived but not epidermal dendritic cells. Eur. J. Immunol. 32:2002;322-332.
65. Liu Y., et al. Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. Nat. Med. 6:2000;1380-1387.
66. Nassar T., et al. Human alpha -defensin regulates smooth muscle cell contraction: a role for low-density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. Blood. 100:2002;4026-4032.
67. Zhang L., et al. Contribution of human {alpha}-defensin-1, -2 and -3 to the anti-HIV-1 activity of CD8 Antiviral Factor. Science. 298:2002;995-1000.
68. Stebbing J., et al. The heat shock protein receptor CD91 is upregulated in monocytes of HIV-1-infected "true" long-term non-progressors. Blood. 101:2003;4000-4004.
69. Rescigno M., Borrow P. The host-pathogen interaction: new themes from dendritic cell biology. Cell. 106:2001;267-270.
70. Huang Q., et al. The plasticity of dendritic cell responses to pathogens and their components. Science. 294:2001;870-875.
71. Rooney C.M., et al. Immunotherapy for Epstein-Barr virus-associated cancers. J. Natl. Cancer Inst. Monogr. 23:1998;89-93.
72. Timmerman J.M., Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. 50:1999;507-529.
73. Oelke M., et al. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat. Med. 9:2003;619-625.
74. Stebbing J., et al. Antibody targeted MHC complex directed expansion of HIV-1 and KSHV-specific CD8 positive lymphocytes: a new approach to therapeutic vaccination. Blood. 2003;. DOI 10.1182/blood-2003-09-3023 ( www.bloodjournal. org ).
75. Savage P., et al. Anti-viral cytotoxic T cells inhibit the growth of cancer cells with antibody targeted HLA class I/peptide complexes in SCID mice. Int. J. Cancer. 98:2002;561-566.
76. Ogg G.S., et al. Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes. Br. J. Cancer. 82:2000;1058-1062.
77. Savage P., et al. Induction of viral and tumour specific CTL responses using antibody targeted HLA class I peptide complexes. Br. J. Cancer. 86:2002;1336-1342.
78. Gajewski T.F., et al. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin. Cancer Res. 7:2001;895s-901s.
79. *0201- restricted CD8+ T-cell epitope for the glycoprotein B homolog of human herpesvirus 8. Blood. 99:2002;3360-3366.